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P
t
RTo the Editor: Increasingly, the practice of medicine has relied on
pplicable and available evidence to deliver quality care. Cardio-
ascular medicine has led the way using numerous clinical trials as
he basis of clinical practice guidelines. However, despite the strong
ssociation of aging with the development of cardiovascular disease,
andomized clinical trials rarely enroll a substantial proportion of older
dults, leading experts to question the applicability of the evidence
ase to the typical patient with cardiovascular disease (1). We sought
to document the inclusion of older adults in contemporary high-
profile, recently conducted clinical trial populations in cardiovascular
disease and compare the age characteristics of the clinical trials with
the age characteristics of the diseases being studied.
All late-breaking clinical trials (LBCTs) at the 2011 American
Heart Association (AHA) Scientific Sessions were included in this
study (2). For each LBCT, a brief summary of the important
results, with all available age information, was extracted. This
represented inclusion or exclusion characteristics on the basis of
age and the age information of the baseline characteristic (means,
medians, and proportions above and below age cut points). The
LBCTs were divided into disease-based categories, and results
were tabulated by category. When available, the published report
for each LBCT was used. In cases in which the reports were not
published, information was obtained from the LBCT slide set on
the AHA Web site (2) and supplemented with information from
ClinicalTrials.gov as needed. To compare the clinical trial cohort
with the community population, the prevalence of older adults in
each disease category was ascertained.
The 22 LBCTs at the 2011 AHA Scientific Sessions were
divided by category: coronary artery disease (5 trials), acute
coronary syndromes (5), chronic heart failure (3), atrial fibrillation
(3), cardiac surgery and intervention (4), peripheral artery disease
(1), and venous thromboembolism (1). Among those trials, 8 did
not include older adults (age 60 to 80 years, depending on the
study). In trials in which the percents of older adults were available,
adults age 75 years constituted 9% to 55% of the enrolled subjects.
In the remaining trials, the mean age was 54 to 66 years. This
contrasts with the prevalence of older age among those with cardio-
vascular diseases in the general population, in which older adults
represent one-third to one-half of patients with the cardiovascular
diseases studied in these trials. See Table 1 (3–25) for details.
With aging of the United States population and the evolving
emographics of cardiovascular disease, we reviewed the LBCTs at
he 2011 AHA Scientific Sessions to determine the ages of enrolled
ubjects and, when available, the percent of older adults included each
rial. Our findings show that in the current era of clinical cardiovas-
ular research, the demographics of those enrolled in the LBCTs are
nconsistent with those of the community population and inade-
uately represent older adults with cardiovascular disease.This report is not the first to raise concern about the enrollment
of older adults in clinical trials in cardiovascular disease (26). Lee
et al. (27) documented the low representation of older adults in
randomized trials of acute coronary syndromes. Kitzman and Rich
(28) identified the low percent of older adults in heart failure research
in comparison with the advanced ages of most patients with heart
failure. The gap in the evidence base for cardiovascular care in older
adults has led experts to call for a new paradigm in the way we
provide cardiac care and in the way we study cardiovascular
disease (1). Nonetheless, this review of LBCTs at the 2011
AHA Scientific Sessions confirms that current high-profile
cardiovascular clinical research still does not address the chal-
lenges of an aging society.
There are several disadvantages to systematically excluding older
adults from clinical trials. When caring for older adults, we are forced
to apply therapies that have not been proven effective in this vulnerable
population. Second, by failing to enroll older and more complicated
patients, the generalizability of the trial results to the broad population
can be questioned. If a therapy shows a small benefit in the context of
a highly selected clinical trial population, how can we reliably translate
those results to the patients we care for, young and old?
In conclusion, the enrollment of older adults in the LBCTs at
the 2011 AHA Scientific Sessions is low and does not reflect the
representation of older adults with cardiovascular disease in the
general population. Despite multiple calls to generate more age-
specific data to better guide management for the older adults most
vulnerable to cardiovascular disease and to cardiovascular disease
management complexities, this need is still not being prioritized in
cutting-edge, premier cardiovascular research efforts.
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Stable coronary heart disease
Population Coronary heart disease prevalence 29% age 75 yrs (3)
Clinical trials “Comparison of the Progression of Coronary Atherosclerosis for Two High Efficacy Statin Regimens
With Different HDL Effects: SATURN Study Results” (4)
Excluded subjects
age 75 yrs
“Lipid-Modulating Effects of Evacetrapib, a Novel CETP Inhibitor, Administered as Monotherapy or
in Combination With the Most Commonly-Used Statins” (5)
Mean age 56 yrs
“Extended-Release Niacin Does Not Reduce Clinical Events in Patients With Established
Cardiovascular Disease Whose LDL-Cholesterol is Optimally Controlled With Statin Therapy:
Results From the AIM-HIGH Trial” (6)
Mean age 64 yrs
“ELEVATE-TIMI 56: Escalating Clopidogrel by Involving a Genetic Strategy-TIMI 56” (7) Excluded subjects
age 75 yrs
“Practice-Based Opportunities for Weight Reduction (POWER)” (8) Mean age 54 yrs
Acute coronary syndromes
Population Incident heart attacks 45% age 75 yrs (9)
Clinical trials “Intracoronary Compared With Intravenous Bolus Abciximab Application During Primary
Percutaneous Coronary Intervention: AIDA STEMI Trial” (source: presentation slides)
18% age 75 yrs
“Abciximab Plus Unfractionated Heparin Versus Bivalirudin in Patients With Non-ST-Segment
Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention.
The ISAR-REACT 4 Randomized Trial” (10)
Excluded subjects
age 80 yrs
“The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome
(TRA*CER) Trial” (11)
17% age 75 yrs
“Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With
Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 51 (ATLAS ACS 2-TIMI 51) Trial:
A Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of
Rivaroxaban in Acute Coronary Syndrome” (12)
9% age 75 yrs
“The Impact of Full Coverage for Preventive Medications After Myocardial Infarction on Recurrent
Vascular Events: The Post-MI Free Rx Event and Economic Evaluation (Post-MI FREEE) Trial” (13)
Excluded subjects
age 65 yrs
Chronic heart failure
Population Incident heart failure 23% age  80 yrs (14)
Clinical trials “Effect of Cardiac Stem Cells in Patients With Ischemic Cardiomyopathy: Interim Results of the
SCIPIO Trial” (15)
Excluded subjects
age 75 yrs
“Double Blind Placebo Controlled Dose Ranging Study of the Efficacy and Safety of Celivarone 50,
100 or 300 mg OD With Amiodarone as Calibrator for the Prevention of ICD Interventions or
Death (ALPHEE)” (16)
Mean age 64 yrs
“Pharmacist Intervention to Prevent Hospitalization and Death in Patients With Heart Failure:
A Prospective Cluster Randomised Controlled Trial” (17)
55% of subjects
age 70 yrs
Atrial fibrillation
Population Atrial fibrillation prevalence 37% age 80 yrs (18)
Clinical trials “Atrial Fibrillation Catheter Ablation Versus Surgical Ablation Treatment:
A multi-Center Randomized Clinical Trial” (19)
Excluded subjects
age 70 yrs
“A Randomized Multicenter Comparison of Radiofrequency Ablation and Antiarrhythmic Drug
Therapy as First-Line Treatment in 294 Patients With Paroxysmal Atrial Fibrillation”
(source: presentation slides)
Excluded subjects
age 70 yrs
“The Results of the PALLAS Study: PALLAS Was Designed to Test Whether Dronedarone Could
Reduce Major Vascular Morbidity and Mortality in Patients With Permanent Atrial Fibrillation
and Previous Vascular Disease or Multiple Risk Factors” (20)
Enrolled subjects
age 65 yrs,
52% age 75 yrs
Cardiac surgery and intervention
Population Cardiac procedures 52% age 65 yrs (9)
Percutaneous coronary intervention 26% age 75 yrs (21)
Clinical trials “Randomized Trial of Early Surgery Versus Conventional Treatment for Infective Endocarditis
(EASE)” (source: presentation slides)
Excluded subjects
age 80 yrs
“Colchicine Reduces Post-Operative Atrial Fibrillation. Results of the COPPS Atrial Fibrillation
Study” (22)
Mean age 66 yrs
“Testing an Evidence-Based, Individualized Informed Consent Form to Improve Patients’
Experiences With PCI” (source: presentation slides)
No information available
“Outcomes of Non-Primary PCI at Hospitals With and Without On-Site Cardiac Surgery:
A Randomized Study” (source: presentation slides)
Mean age 64 yrs
Peripheral vascular disease
Population Peripheral artery disease prevalence 57% age 70 yrs (23)
Incident venous thromboembolism 26% age 75 yrs (24)
Clinical trials “Claudication Treatment Comparative Effectiveness: 6 Month Outcomes From the CLEVER Study”
(source: presentation slides)
Mean age 64 yrs
“Extended Anticoagulant Prophylaxis in Initially Hospitalized Medically Ill Patients:
Results of the ADOPT (Apixaban Dosing to Optimize Protection From Thrombosis) Trial” (25)
30% age 75 yrs
AIDA STEMI Abciximab Intracoronary Versus Intravenously Drug Application in ST-Elevation Myocardial Infarction; AIM-HIGH Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High
Triglycerides: Impact on Global Health; CETP  cholesterol ester transfer protein; CLEVER  Claudication: Exercise Versus Endoluminal Revascularization; COPPS  Colchicine for Prevention of the
Postpericardiotomy Syndrome; HDL  high-density lipoprotein; ISAR-REACT 4  Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 4; MI  myocardial
nfarction; OD  once daily; PALLAS  Permanent Atrial Fibrillation Outcome Study Using Dronedarone on Top of Standard Therapy; SATURN  Study of Coronary Atheroma by Intravascular Ultrasound:
ffect of Rosuvastatin Versus Atorvastatin; SCIPIO  Stem Cell Infusion in Patients With Ischemic Cardiomyopathy.
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Letters to the Editor
Endothelial Function
in Coronary Chronic
Total Occlusions
Need for Rigorous Methodology
We read with interest the paper by Galassi et al. (1). We agree with
the authors about the fact that immediately after chronic total
occlusion (CTO) recanalization, there is an impairment of
endothelium-dependent and -independent vasomotion, as also dem-
onstrated in recent studies (2,3). However, some limitations and flaws
in the methodology and in the results presentation need to be
highlighted and clarified by the authors.
With regard to quantitative coronary angiography (QCA), it is
of value to use 3-dimensional QCA (3D-QCA), which is known
to overcome the limitations of 2-dimensional QCA (2D-QCA),
such as foreshortening, thus making the measurements more
reliable (4). However, it is quite unusual and arbitrary that the
authors measured only the reference vessel diameter (RVD) or that
such measurement was not performed in a coronary segment, but
at 3 single points distal to the stent edge. All previous studies
classically quantified the vasomotion in a coronary segment,
reporting the changes in mean lumen diameter and not in RVD
(5,6). The restriction of the analysis to 3 single QCA points limits
the observation, multiplying the measurements per patients and
not taking into account any data clustering. Moreover, in contrast
to what is reported in the Results section, Table 3 shows the
intravascular ultrasound (IVUS) data and not the QCA data of the
vasomotion substudy.
The coronary segment distal to the CTO was also analyzed by
IVUS. The authors again decided to restrict the observation,
performing the analysis every 5 mm, instead of the conventionally
used 1 mm. Although it is known that the 3D-QCA measure-
ments are closer to the IVUS measurements compared with
2D-QCA, it is noteworthy that in the present study, there was not
an increase in lumen diameter by IVUS in contrast to QCA (7). It
may have to do with the fact that the QCA points do not match
the sampling of IVUS. Nevertheless, this contradictory message
(QCA vs. IVUS) makes their observations much less solid: in the
best scenario, IVUS is much more reliable to quantify lumen
dimensions than QCA and therefore the main conclusion of the
